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Studies have reported an association between pergolide mesylate use and development of valvular heart disease (VHD). Although pergolide has 
been removed from the United States market further insight into symptom presentation may benefit future studies of drug induced VHD. Aims/
Methods:  I) assess accuracy of symptoms in detecting VHD in patients exposed to pergolide. II) determine if a relationship exists between 
increasing doses of pergolide and VHD using the area under the receiver-operating-characteristic curve (AUROC). Parkinson’s disease or movement 
disorder patients exposed to pergolide were identified through a central Kaiser Permanente database. Echocardiography was performed to assess 
for the presence of significant VHD defined as moderate or severe regurgitation. Symptoms were ascertained through a questionnaire. The sensitivity, 
specificity, positive and negative predictive value (PPV, NPV) was calculated. 
Results:  In the cohort of 50 patients VHD prevalence was 26%. Mean age - 67.4 ± 11.4 years. Males and females were equally distributed. 
Symptoms were noted in 84.0% of patients. See table. The AUROC was 0.54 (0.32-0.75). 
Conclusions:  Although exposure to pergolide was associated with symptoms, neither the total dose nor the specific symptom(s) helped determine 
whether significant valvular regurgitation existed. These results suggest echocardiography will be necessary to effectively rule out significant VHD in 
patients exposed to cardiotoxic medications. 
Variable Sensitivity(%, 95% CI) Specificity(%, 95% CI) PPV(%, 95% CI) NPV(%, 95% CI)
Chest pain 23.1(11.4-34.8) 91.9(84.3-99.5) 50.0(36.1-63.9) 77.3(65.7-88.9)
Shortness of Breath 53.9(40.0-67.7) 67.6(54.6-80.5) 36.8(23.5-50.2) 80.7(69.7-91.6)
Lower Extremity Edema 50.0(36.0-64.0) 70.3(57.5-83.1) 35.3(21.9-48.7) 81.3(70.3-92.2)
Any of Above 3 84.6(74.6-94.6) 45.9(32.1-59.8) 35.5(22.2-48.8) 89.5(80.9-97.9)
